We found that midostaurin strongly enhanced rituximab cytotoxicity, especially in the resistant BL cells, by promoting apoptosis, possibly by altering the phosphorylation of downstream signaling molecules, including Bad, Bcl-2 and NF-κB. The gene discussed is BCL2; the disease is Burkitt lymphoma.